Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
Payers' Guide
Tecfidera (Dimethyl Fumarate), a New Oral Therapy Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Loretta Fala
Read More
Payers' Guide
Xiaflex (Collagenase Clostridium Histolyticum), First Drug Approved by the FDA for Peyronie’s Disease
Loretta Fala
Read More
Payers' Guide
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
,
Payers' Guide
The Sixth Annual Payers’ Guide to New FDA Approvals
Read More
Payers' Guide
New FDA Drug Approvals Hit an 18-Year High in 2014
Gary M. Owens, MD
Read More
Drug Updates
,
Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2014
Read More
Drug Updates
,
Payers' Guide
Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes
Loretta Fala
Read More
Drug Updates
,
Payers' Guide
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates
,
Payers' Guide
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Loretta Fala
Read More
Drug Updates
,
Payers' Guide
Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection
Lisa A. Raedler, PhD, RPh
Read More
3
4
5
6
7
8
9
Page 6 of 19
Results 51 - 60 of 185